1 | abstinence | 3,966 |
2 | attendance | 1,631 |
3 | absenteeism | 317 |
4 | non-attendance | 69 |
5 | absences | 57 |
6 | abstention | 54 |
7 | overtime | 41 |
8 | uniforms | 35 |
9 | nonattendance | 34 |
10 | binges | 19 |
11 | evapotranspiration | 12 |
12 | reconsultation | 11 |
13 | exophoria | 9 |
14 | scmc-lys | 9 |
15 | syllabi | 9 |
16 | lne | 7 |
17 | prv/placebo | 7 |
18 | re-attendance | 6 |
19 | time-to-hospitalization | 6 |
20 | c-oxidation | 5 |
21 | mgatp | 5 |
22 | light-masks | 4 |
23 | undercall | 4 |
24 | etomoxir | 3 |
25 | libguide | 3 |
26 | non-attendances | 3 |
27 | post-int | 3 |
28 | rem/lda | 3 |
29 | rr-intervals | 3 |
30 | syndesmophytes/ankylosis | 3 |
31 | 4'-amino-3,5-dihydroxy-trans-stilbene | 2 |
32 | acprs | 2 |
33 | ethanol-extracts | 2 |
34 | fam125b | 2 |
35 | invasive-ventilation-free-days | 2 |
36 | lactoconazole | 2 |
37 | langley | 2 |
38 | minimal-lumen-diameter | 2 |
39 | mva/hiv62b | 2 |
40 | myhre | 2 |
41 | panic-anxiety | 2 |
42 | patient-age | 2 |
43 | post-ebb | 2 |
44 | re-offence | 2 |
45 | rs4951011 | 2 |
46 | working/studying | 2 |
47 | 'experiencing | 1 |
48 | -because | 1 |
49 | 0.12k | 1 |
50 | 0.4848 | 1 |
51 | 0.5-41.3 | 1 |
52 | 1,000:1 | 1 |
53 | 1-3kg/h | 1 |
54 | 1.0095 | 1 |
55 | 1/1006 | 1 |
56 | 10-15mg | 1 |
57 | 10/sec | 1 |
58 | 140min/week | 1 |
59 | 1611-2263ppm | 1 |
60 | 189.1±1.76µg/ml | 1 |
61 | 1:148 | 1 |
62 | 1:200-500 | 1 |
63 | 1:399 | 1 |
64 | 1:5735 | 1 |
65 | 1:579 | 1 |
66 | 2-4/100,000 | 1 |
67 | 2-adamantanone | 1 |
68 | 250ng/ml | 1 |
69 | 3-piperidines | 1 |
70 | 3-pyrrolidines | 1 |
71 | 32.6+/-13.1 | 1 |
72 | 36.5c | 1 |
73 | 55.67±0.26 | 1 |
74 | 58.7° | 1 |
75 | 6.67° | 1 |
76 | 6.8-4.9 | 1 |
77 | 62min | 1 |
78 | 63.7°c | 1 |
79 | 82.00±0.09 | 1 |
80 | 83.7pg/ml | 1 |
81 | a2s3/u/p2s5/s | 1 |
82 | agraria | 1 |
83 | ala-93 | 1 |
84 | apneas/hypopneas | 1 |
85 | attaaa | 1 |
86 | baby-take-home | 1 |
87 | band-offsets | 1 |
88 | botna | 1 |
89 | clinquery | 1 |
90 | cost-benefit-effectiveness | 1 |
91 | degree/ged | 1 |
92 | designet | 1 |
93 | echogenety | 1 |
94 | eclt | 1 |
95 | electrolyses | 1 |
96 | f352c+v368i | 1 |
97 | female-weeks | 1 |
98 | ft* | 1 |
99 | hand-washing-with-soap | 1 |
100 | hav/mmrv | 1 |
101 | hvlt-recall | 1 |
102 | hyperaminoacidemia | 1 |
103 | infarction/area | 1 |
104 | isopreterenol | 1 |
105 | junkies | 1 |
106 | k-bands | 1 |
107 | koos₄ | 1 |
108 | labour.there | 1 |
109 | li17tt4 | 1 |
110 | life-activity | 1 |
111 | lung-medication | 1 |
112 | metformin/thiazolidinedione | 1 |
113 | nf-κb/rela | 1 |
114 | non-progress | 1 |
115 | non-response/non-remission | 1 |
116 | nonappearance | 1 |
117 | nsaids/apap | 1 |
118 | oaths | 1 |
119 | octadecanethiol | 1 |
120 | p300-400 | 1 |
121 | performance-3.12 | 1 |
122 | phase-one | 1 |
123 | pkc-micro | 1 |
124 | policies/rules | 1 |
125 | pressure-development | 1 |
126 | primaquinerelapse | 1 |
127 | profit-or | 1 |
128 | radiation-oncology | 1 |
129 | rates/control | 1 |
130 | ratio=0.56 | 1 |
131 | ratio=1.40 | 1 |
132 | ratio=5 | 1 |
133 | rccn | 1 |
134 | re-herniation | 1 |
135 | realisations | 1 |
136 | received•completion | 1 |
137 | redonation | 1 |
138 | sorocaba | 1 |
139 | spd/spm/glycerol | 1 |
140 | spierfonds | 1 |
141 | strategy-permitting | 1 |
142 | suggilations | 1 |
143 | superchilling | 1 |
144 | talniflumateonducted | 1 |
145 | tcpco2-level | 1 |
146 | tenofovir/lamivudine/efavirenz | 1 |
147 | thehypomethylation | 1 |
148 | ti-4zr-22nb-2sn | 1 |
149 | tissue-toxicity | 1 |
150 | trifluoroacylation | 1 |
151 | visits-a | 1 |
152 | wna | 1 |
153 | ~0.49 | 1 |
154 | ~11.1 | 1 |
155 | ~291.9kb | 1 |
156 | ≥8ppm | 1 |
1 | 'experiencing | 1 |
2 | -because | 1 |
3 | 0.12k | 1 |
4 | 0.4848 | 1 |
5 | 0.5-41.3 | 1 |
6 | 1,000:1 | 1 |
7 | 1-3kg/h | 1 |
8 | 1.0095 | 1 |
9 | 1/1006 | 1 |
10 | 10-15mg | 1 |
11 | 10/sec | 1 |
12 | 140min/week | 1 |
13 | 1611-2263ppm | 1 |
14 | 189.1±1.76µg/ml | 1 |
15 | 1:148 | 1 |
16 | 1:200-500 | 1 |
17 | 1:399 | 1 |
18 | 1:5735 | 1 |
19 | 1:579 | 1 |
20 | 2-4/100,000 | 1 |
21 | 2-adamantanone | 1 |
22 | 250ng/ml | 1 |
23 | 3-piperidines | 1 |
24 | 3-pyrrolidines | 1 |
25 | 32.6+/-13.1 | 1 |
26 | 36.5c | 1 |
27 | 4'-amino-3,5-dihydroxy-trans-stilbene | 2 |
28 | 55.67±0.26 | 1 |
29 | 58.7° | 1 |
30 | 6.67° | 1 |
31 | 6.8-4.9 | 1 |
32 | 62min | 1 |
33 | 63.7°c | 1 |
34 | 82.00±0.09 | 1 |
35 | 83.7pg/ml | 1 |
36 | a2s3/u/p2s5/s | 1 |
37 | absences | 57 |
38 | absenteeism | 317 |
39 | abstention | 54 |
40 | abstinence | 3,966 |
41 | acprs | 2 |
42 | agraria | 1 |
43 | ala-93 | 1 |
44 | apneas/hypopneas | 1 |
45 | attaaa | 1 |
46 | attendance | 1,631 |
47 | baby-take-home | 1 |
48 | band-offsets | 1 |
49 | binges | 19 |
50 | botna | 1 |
51 | c-oxidation | 5 |
52 | clinquery | 1 |
53 | cost-benefit-effectiveness | 1 |
54 | degree/ged | 1 |
55 | designet | 1 |
56 | echogenety | 1 |
57 | eclt | 1 |
58 | electrolyses | 1 |
59 | ethanol-extracts | 2 |
60 | etomoxir | 3 |
61 | evapotranspiration | 12 |
62 | exophoria | 9 |
63 | f352c+v368i | 1 |
64 | fam125b | 2 |
65 | female-weeks | 1 |
66 | ft* | 1 |
67 | hand-washing-with-soap | 1 |
68 | hav/mmrv | 1 |
69 | hvlt-recall | 1 |
70 | hyperaminoacidemia | 1 |
71 | infarction/area | 1 |
72 | invasive-ventilation-free-days | 2 |
73 | isopreterenol | 1 |
74 | junkies | 1 |
75 | k-bands | 1 |
76 | koos₄ | 1 |
77 | labour.there | 1 |
78 | lactoconazole | 2 |
79 | langley | 2 |
80 | li17tt4 | 1 |
81 | libguide | 3 |
82 | life-activity | 1 |
83 | light-masks | 4 |
84 | lne | 7 |
85 | lung-medication | 1 |
86 | metformin/thiazolidinedione | 1 |
87 | mgatp | 5 |
88 | minimal-lumen-diameter | 2 |
89 | mva/hiv62b | 2 |
90 | myhre | 2 |
91 | nf-κb/rela | 1 |
92 | non-attendance | 69 |
93 | non-attendances | 3 |
94 | non-progress | 1 |
95 | non-response/non-remission | 1 |
96 | nonappearance | 1 |
97 | nonattendance | 34 |
98 | nsaids/apap | 1 |
99 | oaths | 1 |
100 | octadecanethiol | 1 |
101 | overtime | 41 |
102 | p300-400 | 1 |
103 | panic-anxiety | 2 |
104 | patient-age | 2 |
105 | performance-3.12 | 1 |
106 | phase-one | 1 |
107 | pkc-micro | 1 |
108 | policies/rules | 1 |
109 | post-ebb | 2 |
110 | post-int | 3 |
111 | pressure-development | 1 |
112 | primaquinerelapse | 1 |
113 | profit-or | 1 |
114 | prv/placebo | 7 |
115 | radiation-oncology | 1 |
116 | rates/control | 1 |
117 | ratio=0.56 | 1 |
118 | ratio=1.40 | 1 |
119 | ratio=5 | 1 |
120 | rccn | 1 |
121 | re-attendance | 6 |
122 | re-herniation | 1 |
123 | re-offence | 2 |
124 | realisations | 1 |
125 | received•completion | 1 |
126 | reconsultation | 11 |
127 | redonation | 1 |
128 | rem/lda | 3 |
129 | rr-intervals | 3 |
130 | rs4951011 | 2 |
131 | scmc-lys | 9 |
132 | sorocaba | 1 |
133 | spd/spm/glycerol | 1 |
134 | spierfonds | 1 |
135 | strategy-permitting | 1 |
136 | suggilations | 1 |
137 | superchilling | 1 |
138 | syllabi | 9 |
139 | syndesmophytes/ankylosis | 3 |
140 | talniflumateonducted | 1 |
141 | tcpco2-level | 1 |
142 | tenofovir/lamivudine/efavirenz | 1 |
143 | thehypomethylation | 1 |
144 | ti-4zr-22nb-2sn | 1 |
145 | time-to-hospitalization | 6 |
146 | tissue-toxicity | 1 |
147 | trifluoroacylation | 1 |
148 | undercall | 4 |
149 | uniforms | 35 |
150 | visits-a | 1 |
151 | wna | 1 |
152 | working/studying | 2 |
153 | ~0.49 | 1 |
154 | ~11.1 | 1 |
155 | ~291.9kb | 1 |
156 | ≥8ppm | 1 |
1 | ft* | 1 |
2 | 2-4/100,000 | 1 |
3 | p300-400 | 1 |
4 | 1:200-500 | 1 |
5 | ratio=1.40 | 1 |
6 | ~11.1 | 1 |
7 | 32.6+/-13.1 | 1 |
8 | rs4951011 | 2 |
9 | 1,000:1 | 1 |
10 | performance-3.12 | 1 |
11 | 0.5-41.3 | 1 |
12 | ala-93 | 1 |
13 | li17tt4 | 1 |
14 | 1:5735 | 1 |
15 | 1.0095 | 1 |
16 | ratio=5 | 1 |
17 | 1/1006 | 1 |
18 | 55.67±0.26 | 1 |
19 | ratio=0.56 | 1 |
20 | 1:148 | 1 |
21 | 0.4848 | 1 |
22 | 6.8-4.9 | 1 |
23 | 82.00±0.09 | 1 |
24 | ~0.49 | 1 |
25 | 1:579 | 1 |
26 | 1:399 | 1 |
27 | visits-a | 1 |
28 | attaaa | 1 |
29 | sorocaba | 1 |
30 | rem/lda | 3 |
31 | infarction/area | 1 |
32 | hyperaminoacidemia | 1 |
33 | agraria | 1 |
34 | exophoria | 9 |
35 | nf-κb/rela | 1 |
36 | botna | 1 |
37 | wna | 1 |
38 | mva/hiv62b | 2 |
39 | fam125b | 2 |
40 | post-ebb | 2 |
41 | ~291.9kb | 1 |
42 | 36.5c | 1 |
43 | 10/sec | 1 |
44 | 63.7°c | 1 |
45 | degree/ged | 1 |
46 | talniflumateonducted | 1 |
47 | attendance | 1,631 |
48 | re-attendance | 6 |
49 | non-attendance | 69 |
50 | nonattendance | 34 |
51 | nonappearance | 1 |
52 | re-offence | 2 |
53 | abstinence | 3,966 |
54 | libguide | 3 |
55 | patient-age | 2 |
56 | lactoconazole | 2 |
57 | overtime | 41 |
58 | baby-take-home | 1 |
59 | 4'-amino-3,5-dihydroxy-trans-stilbene | 2 |
60 | lne | 7 |
61 | phase-one | 1 |
62 | metformin/thiazolidinedione | 1 |
63 | 2-adamantanone | 1 |
64 | labour.there | 1 |
65 | myhre | 2 |
66 | primaquinerelapse | 1 |
67 | -because | 1 |
68 | 10-15mg | 1 |
69 | 'experiencing | 1 |
70 | superchilling | 1 |
71 | strategy-permitting | 1 |
72 | working/studying | 2 |
73 | 1-3kg/h | 1 |
74 | f352c+v368i | 1 |
75 | syllabi | 9 |
76 | 0.12k | 1 |
77 | 140min/week | 1 |
78 | tcpco2-level | 1 |
79 | hvlt-recall | 1 |
80 | undercall | 4 |
81 | 250ng/ml | 1 |
82 | 83.7pg/ml | 1 |
83 | 189.1±1.76µg/ml | 1 |
84 | octadecanethiol | 1 |
85 | isopreterenol | 1 |
86 | spd/spm/glycerol | 1 |
87 | rates/control | 1 |
88 | 1611-2263ppm | 1 |
89 | ≥8ppm | 1 |
90 | absenteeism | 317 |
91 | rccn | 1 |
92 | 62min | 1 |
93 | non-response/non-remission | 1 |
94 | lung-medication | 1 |
95 | c-oxidation | 5 |
96 | re-herniation | 1 |
97 | trifluoroacylation | 1 |
98 | thehypomethylation | 1 |
99 | redonation | 1 |
100 | evapotranspiration | 12 |
101 | reconsultation | 11 |
102 | time-to-hospitalization | 6 |
103 | received•completion | 1 |
104 | abstention | 54 |
105 | ti-4zr-22nb-2sn | 1 |
106 | prv/placebo | 7 |
107 | pkc-micro | 1 |
108 | hand-washing-with-soap | 1 |
109 | nsaids/apap | 1 |
110 | mgatp | 5 |
111 | minimal-lumen-diameter | 2 |
112 | etomoxir | 3 |
113 | profit-or | 1 |
114 | a2s3/u/p2s5/s | 1 |
115 | apneas/hypopneas | 1 |
116 | k-bands | 1 |
117 | spierfonds | 1 |
118 | non-attendances | 3 |
119 | absences | 57 |
120 | binges | 19 |
121 | junkies | 1 |
122 | policies/rules | 1 |
123 | 3-pyrrolidines | 1 |
124 | 3-piperidines | 1 |
125 | electrolyses | 1 |
126 | oaths | 1 |
127 | syndesmophytes/ankylosis | 3 |
128 | female-weeks | 1 |
129 | light-masks | 4 |
130 | rr-intervals | 3 |
131 | uniforms | 35 |
132 | suggilations | 1 |
133 | realisations | 1 |
134 | acprs | 2 |
135 | cost-benefit-effectiveness | 1 |
136 | non-progress | 1 |
137 | ethanol-extracts | 2 |
138 | band-offsets | 1 |
139 | invasive-ventilation-free-days | 2 |
140 | scmc-lys | 9 |
141 | designet | 1 |
142 | eclt | 1 |
143 | pressure-development | 1 |
144 | post-int | 3 |
145 | hav/mmrv | 1 |
146 | langley | 2 |
147 | radiation-oncology | 1 |
148 | clinquery | 1 |
149 | panic-anxiety | 2 |
150 | echogenety | 1 |
151 | tissue-toxicity | 1 |
152 | life-activity | 1 |
153 | tenofovir/lamivudine/efavirenz | 1 |
154 | koos₄ | 1 |
155 | 58.7° | 1 |
156 | 6.67° | 1 |